BREAKING: FDA approves Pfizer Covid booster for kids 5 to 11 despite ‘vaccine offering little protection’.
Children 5 to 11 are eligible for a Pfizer booster at least five months after receiving the two-dose series, the FDA announced
Children in that age group are eligible for a booster at least five months after receiving the two-dose Pfizer series, the FDA stated on Tuesday morning. The booster is 10 micrograms, which is the same amount as the two-shot series for the same age group and the third shot for people 12 years and older.
The FDA’s approval comes despite a February study showing that two doses of the vaccine provided little protection against the Omicron variant.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Abbott Reaches Agreement With FDA to Reopen Baby Formula Plant to Ease Nationwide ShortageBREAKING: Abbott has reached an agreement with the FDA to reopen its manufacturing plant in Michigan to help ease a nationwide shortage of baby formula, the company announced.
Read more »
Children’s activity levels have not recovered after end of Covid restrictions – studyOnly about a third of children and young people are meeting recommended activity levels, Bristol study finds
Read more »
Next and Wagamama face investor backlash over CEO bonuses‘Red top’ warning over payouts for Simon Wolfson and Andy Hornby after chains given Covid support
Read more »
Children’s physical activity levels stuck below guidelines after Covid lockdownsResearch shows that 10 and 11-year-olds average just 56 minutes of moderate to vigorous daily activity on weekdays
Read more »
Shanghai to end Covid lockdown and return to normal life in June amid economic slowdownAuthorities say restrictions to ease in stages after extended lockdown that has sent shockwaves through Chinese economy and global supply chains
Read more »
Ryanair warns of ‘fragile’ recovery as Ukraine war and Covid push it to lossMichael O’Leary says airline hopes to return to ‘reasonable profitability’ but declines to make forecasts
Read more »